Ulcerative Colitis

Latest News

Marijuana and IBD: Challenging Decisions

By

Andy Kistler, MD, PharmD

Though patient use of cannabinoids for the treatment of IBD has increased, clinical decision making on whether to formally recommend it as treatment remains difficult.

Fecal DPP-4 Level May Be Biomarker for IBD

By

Colby Stong

Researchers aimed to better elucidate the role of fDPP-4 levels as a biomarker of IBD activity and to correlate it with certain clinical parameters.

Study Explores Links Between Diet, Gut Microbiome, and Inflammation

Diet directly impacts the gut microbiome, which directly affects inflammatory responses in the gut.

Anxiety and Depression Common in Patients With IBD

By

Colby Stong

Researchers assessed the prevalence of symptoms of anxiety and depression in adult patients with irritable bowel disease.

Upadacitinib Meets End Points in Ulcerative Colitis Trial

By

Brian Park, PharmD

The U-ACCOMPLISH induction study evaluated the efficacy and safety of upadacitinib in 515 adults with moderate to severe ulcerative colitis.

Low Rates of GI-Related AEs in Patients With PsA, AS Initiating Secukinumab

By

Amit Akirov, MD

Researchers evaluated gastrointestinal-related adverse events in patients with psoriatic arthritis and ankylosing spondylitis who were initiating secukinumab.

IBD Treatment Options for Patients With EIMs

By

Jessica Nye, PhD

Researchers summarized the current knowledge on treatment options for extraintestinal manifestations in patients with IBD, while calling attention to gaps in the research.

Opioids and IBD: Current Challenges

By

C. Andrew Kistler, MD, PharmD

Initiation of opioid use during a flare of symptoms can eventually lead to chronic opioid use (COU), which can have detrimental effects on a patient’s IBD, as well as their overall clinical health.

Induction Therapy for UC with ABX464 Proves Safe and Effective

By

Virginia A. Schad, PharmD, RPh

Researchers conducted a phase 2a study to determine the safety and efficacy of ABX464 in patients with moderate to severe ulcerative colitis.

Depression May Predate IBD

By

Vincent Soreca

Researchers investigated whether psychological comorbidities predated the diagnosis and propagation of inflammatory bowel disease.

Pouchitis, Pouch Failure with PSC-UC

By

Virginia A. Schad, PharmD, RPh

Investigators compared rates of pouchitis and pouch failure among patients with and without primary sclerosing cholangitis.

The Intersection of HIV and IBD: A Unique Patient Population

By

C. Andrew Kistler, MD, PharmD

The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.

Tofacitinib: Safe, Effective Treatment for Severe UC

By

Jessica Nye, PhD

Researchers analyzed the effectiveness of tofacitinib for the treatment of moderate to severe ulcerative colitis.

Collagenous Colitis Subtype Linked to Increased Risk for Severe COVID-19

By

Brandon May

Researchers assessed the risk for severe COVID-19 in patients with microscopic colitis vs the general population.

Anti-Integrin αvβ6 Antibodies Used to Diagnose and Monitor UC

By

Virginia A. Schad, PharmD, RPh

Investigators assessed whether patients with UC had autoantibodies against integrin αvβ6, a highly specific and sensitive diagnostic biomarker.

Humira Approved for Pediatric Ulcerative Colitis

By

Brian Park, PharmD

The pediatric approval was based on data from the multicenter, randomized, double-blind phase 3 ENVISION I study.

Assessment of Acute Severe Ulcerative Colitis During the COVID-19 Pandemic

By

Vincent Soreca

The PROTECT-ASUC Study Group conducted a multicenter, observational, case-control study to assess the impact of the COVID-19 pandemic on the management of acute severe ulcerative colitis.

Influence of PPI Therapy on Outcome of Infliximab Therapy in IBD

By

Virginia A. Schad, PharmD, RPh

A team of investigators sought to determine how concomitant proton pump inhibitor treatment influences response to infliximab therapy in patients with inflammatory bowel disease.

Kidney Function Monitoring Strategy to Prevent 5-ASA Nephrotoxicity in IBD

By

Vincent Soreca

Investigators performed a literature review of current strategies for monitoring kidney function in patients undergoing treatment with 5-ASA for inflammatory bowel disease.

Ozanimod Gets Priority Review for Ulcerative Colitis

By

Brian Park, PharmD

The submission is supported by data from the True North trial that assessed ozanimod as an induction and maintenance therapy for adults with moderately to severely active UC who had an inadequate response to prior treatment.